GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
- First Posted Date
- 2004-07-13
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 439
- Registration Number
- NCT00087529
A Safety and Efficacy Study of Xolair in Peanut Allergy
Phase 2
Terminated
- Conditions
- Allergy
- First Posted Date
- 2004-07-09
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00086606
- Locations
- 🇺🇸
Trial Information Support Line, Denver, Colorado, United States
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
Phase 2
Completed
- Conditions
- Renal Cell CarcinomaMetastases
- First Posted Date
- 2004-04-20
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00081614
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸Raleigh Hematology Oncology, Raleigh, North Carolina, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Phase 2
Completed
- Conditions
- Idiopathic Pulmonary FibrosisPulmonary Fibrosis
- Interventions
- First Posted Date
- 2004-03-26
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT00080223
Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00005635
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis
Phase 2
Completed
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2008-06-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT00079742
A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2009-09-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT00077870
Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2003-12-15
- Last Posted Date
- 2013-05-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 465
- Registration Number
- NCT00074438
A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers
Phase 1
Completed
- Conditions
- Foot Ulcer
- First Posted Date
- 2003-09-26
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00069446
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT00063154
- Locations
- 🇺🇸
Memorial-Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath